Analysis of Business Model
CIPLA | |
|
CIPLA PHARMACUETICALS
INTRODUCTION
In the year 1935, the Chemical, Industrial and Pharmaceutical Company came into existence named Cipla. The company was founded by Khwaja Abdul Hamied which was registered as public limited company with a capital of Rs. 6 Lakhs. Every year this industry produces drugs worth Rs. 18000 Crores with a profit of 9%. There are 20000 production units in the home countryand the products are exported all over the world at a cheaper price than other international companies. It soon became the top bestselling producers of generic products within the country.Cipla has a flat organisation structure. The firm consists of a large number of educated manpower which is highly skilled and updated with the new methodologies and systems. The foreign capital investment is open as stated in the foreign policy of the country. Cipla is largely divided into three segments formulations, bulk drugs and technology services. The business model of Cipla pharmaceuticals also focuses on the international strategic alliance pursuing organic growth by reducing capital and risks(Anon., 2005).
Q1. Drawing on relevant academic literature and using relevant financial and other information, outline Cipla’s current business model and explain why and how it has changed in the last few years.
Cipla pharmaceutical is the largest drugs manufacturing unit in the markets for bulk drugs and formulations. The business model Cipla Pharmaceuticals has attained an esteem growth in Anti-infective and Anti-asthmatic formulations. The company is the major exporter various products like the raw material, intermediates, prescriptive products, over the country products (OTC) and veterinary products across 150 countries and also provides the technology used in the products and processes(Anon., 2005). Cipla pharmaceutical is a large company with lot of segments, following various strategies and policies to accomplish the needs of the customer and strengthen
|
CIPLA PHARMACUETICALS
INTRODUCTION
In the year 1935, the Chemical, Industrial and Pharmaceutical Company came into existence named Cipla. The company was founded by Khwaja Abdul Hamied which was registered as public limited company with a capital of Rs. 6 Lakhs. Every year this industry produces drugs worth Rs. 18000 Crores with a profit of 9%. There are 20000 production units in the home countryand the products are exported all over the world at a cheaper price than other international companies. It soon became the top bestselling producers of generic products within the country.Cipla has a flat organisation structure. The firm consists of a large number of educated manpower which is highly skilled and updated with the new methodologies and systems. The foreign capital investment is open as stated in the foreign policy of the country. Cipla is largely divided into three segments formulations, bulk drugs and technology services. The business model of Cipla pharmaceuticals also focuses on the international strategic alliance pursuing organic growth by reducing capital and risks(Anon., 2005).
Q1. Drawing on relevant academic literature and using relevant financial and other information, outline Cipla’s current business model and explain why and how it has changed in the last few years.
Cipla pharmaceutical is the largest drugs manufacturing unit in the markets for bulk drugs and formulations. The business model Cipla Pharmaceuticals has attained an esteem growth in Anti-infective and Anti-asthmatic formulations. The company is the major exporter various products like the raw material, intermediates, prescriptive products, over the country products (OTC) and veterinary products across 150 countries and also provides the technology used in the products and processes(Anon., 2005). Cipla pharmaceutical is a large company with lot of segments, following various strategies and policies to accomplish the needs of the customer and strengthen
References: 1. Agarawal, P. & Saibaba, P., 2001. TRIPs and Indian pharmaceutical industry. Economic and political weekly, 36(39), pp. 3787-3790. 2. Anon., 2000. Gearing up for growth. Economic and political weekly, 35(24), p. 1981. 3. Anon., 2001. R and D based growth. Economic and political weekly, 36(1), pp. 9-10. 4. Anon., 2005. CIpla.com. [Online] Available at: www.cipla.com/corporateprofile/financial/pdf/cipla_ar_2004_05pdf 5. Anon., 2005. Export Elixir. Economic and political weekly, 40(6), p. 493. 6. Anon., 2005. Import Export drivers. Economic and political weekly, 40(26), p. 2644. 7. Anon., 2005. Indian Pharma Titan. Economic and political wekly, 40(48), p. 4964. 8. Anon., 2006. Kpmg.com. [Online] Available at: www.in.kpmg.com/pdf/indian%20pharma%20outlook.pdf 9. Anon., 2010. Avendus. [Online] Available at: www.avendus.com/upload/researchreports/CIPLAAV151010.pdf 10. Anon., 2011. Cipla limited. [Online] Available at: www.ndaindia.com/admin/upload_docs/1297934106_cipla%20limited.pdf 11. Anon., 2011. Cipla.com. [Online] Available at: www.cipla.com/corporateprofile/financial/pdf/cipla_ar_2010_11.pdf 14. Greene, W., 2007. The emergence of India 's pharamceutical industry and implications for the U.S. generic drug market. Office of economic, Volume 2007-05-A. 15. Joshi, H. N., 2005. Analysis of the Indian pharmaceutical industry. [Online] Available at: http://tarainnovations.com/yahoo_site_admin/assets/docs/analysisindianpharma.85135952.pdf 17. Lalitha, N., 2002. Indian pharmaceutical industry in WTO regime: a SWOT analysis. Economic and political weekly, 37(34), pp. 3542-3555. 18. Mcconaghie, A., 2009. Inpharm. [Online] Available at: www.inpharm.com/news/copying-each-other-business-models 19. Rane, W., 1997. High cost, low efficiency medicines. Economic and political wekly, 32(51), p. 3251. 21. Shrivastava, B., 2006. Cipla.com. [Online] Available at: www.cipla.com/whatsnew/news01.htm 22. Weill, P. et al., 2004. Do some business models perform better then others. Sloan school of management Massachusetts institute of technology, Volume 226.